Blood cancers
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
Where to go
1 hospital in India taking patients for this trial.
Registry summary (technical)
Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety. The main questions it aims to answer are - 1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage? 2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml? 3. Does leflunomide prevent the need to start pre-emptive therapy for …
Sponsor: Tata Memorial Centre
NCT07709013 on ClinicalTrials.gov
Last updated on the registry 16 Jul 2026 · read by us 20 Oct 2026